PDCD1 and non-small cell lung carcinoma: The combination of ociperlimab plus the anti-PD-1 antibody tislelizumab (BGB-A317) is currently under evaluation in patients diagnosed with distinct advanced or metastatic tumors, including NSCLC, esophageal squamous cell carcinoma, and cervical cancer.